NIKKEI 225
38,160.41 -113.64 (-0.30%) HANG SENG
17,817.93 +54.90 (+0.31%) CRUDE OIL
79.25 +0.25 (+0.32%) GOLD FUTURES
2,333.00 +22.00 (+0.95%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,645.27 -2,221.51 (-4.64%)
ABIVAX Société Anonyme (AAVXF)
| Previous close | 15.15 |
| Open | 15.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 15.15 - 15.15 |
| 52-week range | 10.19 - 20.00 |
| Volume | |
| Avg. volume | 32 |
| Market cap | 998.297M |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.67 |
| Earnings date | 08 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireAbivax publishes financial reports with the French and U.S. securities regulatory agencies
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d’Enregistr
- Globe Newswire
Abivax reports 2023 financial results and operational update
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR 223.3M initial public offering on the Nasdaq Global MarketSufficient funds to finance operations into Q4 2025, including through the announcement of top-line data from the Phase 3 ABTECT induction trials of obefazimod in ulcerative colitis (UC)Implementation of U.S. and European operational infrastruct
- Globe Newswire
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality. Ms. Sharma
